[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Cytrellis Biosystems, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":80},{"warningLetters":4,"total":79},[5,34,58],{"id":6,"raw":7,"subject":15,"body_html":16,"body_text":17,"firm_name":18,"letter_id":19,"created_at":20,"fei_number":21,"letter_url":22,"updated_at":23,"action_type":24,"case_status":25,"posted_date":26,"marcs_cms_no":27,"product_type":28,"closeout_date":29,"issuing_office":11,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":21,"reference_number":21,"action_taken_date":33,"medical_device_id":21,"response_letter_date":21},2523,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2022-08-09T13:20:00Z\">08\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalley-biosystems-632553-08032022\">Valley Biosystems\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Bioresearch Monitoring Program\u003Cbr \u002F>\r\n","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalley-biosystems-632553-10142022\">\u003Ctime datetime=\"2022-10-18T04:00:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","Bioresearch Monitoring Program","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Granger G. C. Hwa, M.D. Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Valley Biosystems\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1265 Triangle Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Sacramento\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95605\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBER-22-002\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Hwa:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during a Food and Drug Administration (FDA) inspection conducted at Valley Biosystems, West Sacramento, California between August 26 and October 8, 2021. FDA investigators met with your staff during the inspection to review your firm’s conduct of the following nonclinical Good Laboratory Practice (GLP) studies:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>FDA conducted this inspection under the Bioresearch Monitoring Program, which includes inspections designed to review the conduct of research involving investigational products and to help ensure that the data are scientifically valid and accurate, in accordance with Title 21 of the Code of Federal Regulations (CFR), Part 58 – Good Laboratory (GLP) regulations (available at \u003Cstrong>eCFR :: 21 CFR Part 58 -- Good Laboratory Practice for Nonclinical Laboratory Studies\u003C\u002Fstrong>), which are requirements promulgated under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262, and section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355, among other provisions. You were not present in person during the inspection but were available via Zoom on September 2, 2021, and October 8, 2021. At the end of the inspection, the FDA investigator presented a Form FDA 483, List of Inspectional Observations (Form FDA 483) and discussed the listed observations with you and your staff.\u003C\u002Fp>\n\n\u003Cp>Based on our review of the Establishment Inspection Report (EIR), the documents submitted with that report, and your firm’s response dated November 1, 2021, to the Form FDA 483 (“Response Letter”), signed by Mr. Cello, we determined that you violated GLP regulations in 21 CFR Part 58. The violations include, but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to ensure that each individual engaged in the conduct of or responsible for the supervision of a nonclinical laboratory study has education, training, and experience, or a combination thereof, to enable that individual to perform the assigned functions; that each testing facility maintains a current summary of training and experience and job description for each individual engaged in or supervising the conduct of a nonclinical laboratory study; and that for each nonclinical laboratory study, a scientist or other professional of appropriate education, training, and experience, or combination thereof, shall be identified as the study director. [21 CFR §§ 58.29(a), 58.29(b), and 58.33].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to maintain records of trainings that your staff had received to adequately assess their competency and qualifications to perform their assigned tasks for Studies&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Examples, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. There is no documentation of protocol-specific trainings for the following individuals who participated in these studies:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Dr. GGCH, the Chairman of the Board, and Test Facility Management who was involved in editing and reviewing the final reports for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Three (3) Veterinarians\u003C\u002Fli>\n\t\u003Cli>Gross Pathologist\u003C\u002Fli>\n\t\u003Cli>Operations Manager\u003C\u002Fli>\n\t\u003Cli>Director of Animal Program &amp; Facilities &amp; Chief Operating Officer\u003C\u002Fli>\n\t\u003Cli>QA Manager\u003C\u002Fli>\n\t\u003Cli>Nine (9) Research Technicians\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>b. Your firm failed to adequately fulfill your regulatory responsibilities by assuring that your study director is qualified and appointed to be the single point of control for Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your QA Manager (hereafter referred to as the Quality Assurance Unit (QAU)) stated that your firm’s study director is not a position and is a title on an “as needed” basis.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you expanded your pre-project planning meetings and required Read Only Trainings for all protocols and protocol amendments. We also reviewed your SOP QA25.4, submitted with your Response Letter, and it appears adequate, if properly implemented.\u003C\u002Fp>\n\n\u003Cp>Your firm has also assigned the supplemental GLP training CAPA PA-21-072-01, which was expected to be completed on or before January 31, 2021. We request that you provide all documentation of the GLP training that you have stated to be completed on or before January 31, 2022, including the materials used for the trainings.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you restated your position that the study director is a title at Valley Biosystems, but not a position, and that you therefore do not plan to create a Study Director position description. This approach is not compliant with the applicable requirements. In response to this letter, please review 21 CFR § 58.33, which sets forth the regulatory requirements for the role of the study director, and inform FDA how you intend to comply with this and the other GLP requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The study director failed to assure that the protocol, including any change, is approved as provided by 21 CFR § 58.120 and is followed; that all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and that unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and corrective action is taken and documented. Additionally, all data entries shall be dated on the date of entry and signed or initialed by the person entering the data. Any change in entries shall be made so as not to obscure the original entry, shall indicate the reason for such change, and shall be dated and signed or identified at the time of the change. [21 CFR § 58.33 (a)(b)(c) and 21 CFR 58.130(e)]\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>a. The study director failed to assure that the study was conducted according to the protocol and was accurately recorded. Specifically, the section of the study #\u003Cstrong>(b)(4)\u003C\u002Fstrong> protocol entitled, “Monitoring of Animal Welfare” required that “signs of animal illness, injury, or pain and distress will be communicated to the Study Director and Sponsor Monitor” and “Recommendations for the treatment of the animals must be approved by the Study Director and Sponsor Monitor.” However, it was not documented that these requirements were met for the following animals:\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> – hemorrhagic diarrhea on 3\u002F2\u002F19 – 3\u002F4\u002F19 and treatment with&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> on 3\u002F2\u002F19.\u003C\u002Fli>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> –treatment with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for trichuris infection on 5\u002F9\u002F19.\u003C\u002Fli>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> – treatment with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for trichuris infection on 1\u002F2\u002F19.\u003C\u002Fli>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> – treatment with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for trichuris infection on 1\u002F2\u002F19.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>b. A review of 12 of 12 of the Test Article (TA)\u002FControl Article (CA) Preparation Forms revealed that the name, lot number, and expiration date of reagents and solutions used in preparation of test and control articles were preprinted as opposed to being documented contemporaneously. The documents revealed that the preprinted expiration dates were crossed out and changed, without explanation, by the study director to reflect different expiration dates over a month after the actual date of preparation. This occurred for the following animal source records:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Animal ID\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date of TA\u002FCA Preparation&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Completed\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>of change\u002Ffootnote\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F3\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F5\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F4\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F10\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F6\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F9\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F12\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F16\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F11\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>10\u002F2\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F17\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F18\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F19\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>Because you failed to ensure that all experimental data were accurately recorded and verified, and that all entries and changes in entries were properly documented, FDA has concerns about the integrity of the data generated from the nonclinical toxicity studies conducted at your testing facility.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you listed SOPs that were revised or are being developed since the inspection, including the revised SOP PA01.7. In your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs not already provided, and documentation of any related trainings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure of the QAU to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection. [21 CFR § 58.35(b)(3)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The QAU is responsible for monitoring each study to assure management that the facilities, equipment, personnel, methods, practices, records, and controls are in conformance with the GLP regulations. 21 CFR § 58.35(a).\u003C\u002Fp>\n\n\u003Cp>a. Your QAU failed to maintain a complete copy of the audit schedule sheet to inspect studies at intervals adequate to assure the integrity of the studies.\u003C\u002Fp>\n\n\u003Cp>b. Your QAU failed to maintain contemporaneously signed and dated documentation or reports of the Critical Phase inspections. Your QAU stated that the Critical Phase inspection results were written directly on the Protocols or on scratch pieces of paper that were thrown away after summarizing the results on the monthly Quality Assurance Status Reports.\u003C\u002Fp>\n\n\u003Cp>Your QAU was not able to provide any source documents of the schedule nor reports for the Critical Phase inspections that were performed for the two GLP studies. We are unable to verify that your QAU audits were adequately conducted according to your SOPs and are in compliance with applicable GLP regulations.\u003C\u002Fp>\n\n\u003Cp>A reliable QAU is integral to the successful completion of any GLP study. Without appropriate QAU oversight, the sponsor and FDA reviewers have no assurance that what is reported in the final study report is accurate. Failure to perform QAU functions calls into question the integrity of both studies.\u003C\u002Fp>\n\n\u003Cp>Your Response Letter explains that you revised SOP QA 10.4 and the accompanying forms; however, you have not developed effective, contemporaneous audit documents that will serve as source documentation of the audits performed by your QAU, for each Critical Phase defined by your SOP. In your response to this letter, please provide audit document templates to accompany your SOP that will serve to demonstrate full compliance with the regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to retain all raw data, documentation, protocols, final reports, and specimens (except those specimens obtained from (b)(4)\u003C\u002Fstrong>\u003Cstrong>&nbsp;tests and (b)(4)\u003C\u002Fstrong>\u003Cstrong>) generated as a result of a nonclinical laboratory study. [ 21 CFR § 58.190(a)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>a. Twelve (12) of 48 animals surgically treated with the test or control article were missing original source Laboratory Animal Anesthesia Records, which contain details of the surgical procedure for test or control article administration. According to your QAU, the original paper records were discarded once they were scanned and saved electronically.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to preserve any source records demonstrating your study director’s adherence to the GLP requirements in regard to his conduct of writing the final reports for Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm was not able to provide the redline copies of the draft reports, and your QAU stated that the documents had all been deleted.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you stated that your SOPs are being revised following the inspection, but you did not provide supporting documentation of your corrective and preventive actions. Please note that good record keeping and an organized archive that allows for the expedient retrieval of raw data are ways in which your firm can ensure the quality and integrity of the data generated from your GLP nonclinical studies.\u003C\u002Fp>\n\n\u003Cp>Incorrect archiving of study materials affects the integrity and reliability of study data as it prevents accurate retrieval of such data for review, analysis, and verification. Also, failure to have an index prevents data from being readily available, located expeditiously, analyzed, and reconciled when necessary.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs for archiving source documents, and documentation of any trainings related to this violation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to include in the final report a description of all circumstances that may have affected the quality or integrity of the data for each nonclinical laboratory study. [21 CFR § 58.185(a)(9)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to include all data observed for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the final Study Report. Data that were not included in the final report include, but are not limited to:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Animal&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Number\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Source Document\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Assessment\u002FComment\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Assessment&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>\u003Cspan>(b)(4)\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Daily Clinical&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Observations\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Nervous tapping\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F20\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>\u003Cspan>(b)(4)\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Functional&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Observation&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Battery&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Evaluation\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Day 122 post-dose “Out-of Cage”&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>assessment documented abnormal&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>dysmetria, specifically a new&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>comment of “mild crouching of torso&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>when walking tripedally.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>1\u002F16\u002F20\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>\u003Cspan>(b)(4)\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Animal Health&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Record\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Acute emesis\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>02\u002F19\u002F20\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>We acknowledge in your Response Letter that you plan to revise SOP QA08.4, Preparation, Review and Approval of Nonclinical Laboratory Study Reports. However, your response cannot be evaluated due to lack of supporting documentation. Please provide a copy of the revised SOP, which you stated will be completed before December 03, 2021, along with documentation of any corrective actions you have implemented thus far.\u003C\u002Fp>\n\n\u003Cp>The records and final study report of an investigation are crucial to the reconstruction of events leading to the collection and reporting of the data and must reflect the procedure and condition of the study. The information in these essential documents form the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\u003C\u002Fp>\n\n\u003Cp>We further note during the inspection that the FDA investigators found five (5) reports, “Project Observation Note” (PON), from \u003Cstrong>(b)(4)\u003C\u002Fstrong> was the laboratory that you contracted to perform histopathology and immunohistochemical analysis for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These records revealed numerous comments of poor-quality and insufficient tissue collections received from your firm. Examples of these deviations noted in the PON report from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>For Week-5 Animals, various deficiencies were noted for all spinal cords, all eye tissues, all kidney tissues, all heart tissues, and all larynx tissues.\u003C\u002Fli>\n\t\u003Cli>For unscheduled death Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong>, various observations were noted for ureters, salivary gland, adrenal, heart, femur\u002Fsternum bone and marrow, and kidneys.\u003C\u002Fli>\n\t\u003Cli>For the animals sacrificed at 13 weeks, all brain \u003Cstrong>(b)(4)\u003C\u002Fstrong> were received with a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, except for a few animals. It appears the \u003Cstrong>(b)(4)\u003C\u002Fstrong> after processing. In addition, for a certain group of four animals, only one liver was received with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response to this letter, we request that you provide all documentation and reports, including any corrective action taken that will demonstrate your firm’s investigation and corrective actions taken regarding the numerous tissue sample collection deviations reported to you by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of your violations and provides you an opportunity to address the above deficiencies. You should investigate and determine the causes of any violations and take prompt actions to implement corrections to prevent the recurrence of similar violations in current and future studies conducted at your GLP nonclinical laboratory.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your nonclinical studies of investigational new drugs. It is your responsibility to ensure full compliance with the law, including all applicable requirements of the FD&amp;C Act, the PHS Act, and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter. In your response, please provide written documentation of additional actions you have taken or will take to correct the noted violations and to prevent the recurrence of similar violations in current and future nonclinical laboratory studies.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. Failure to respond to this letter and to take appropriate corrective action could result in FDA taking regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to me at the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., WO71-G112, Silver Spring, MD 20993-0002. If you have any questions regarding this letter, please contact the Division of Inspections and Surveillance, CBER at 240-402-8038.\u003C\u002Fp>\n\n\u003Cp>We also request that you send a copy of your response to the FDA Office listed below.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza, JD\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nEric Pittman, Director\u003Cbr>\nFDA ORA-BIMO West\u003Cbr>\n550 West Jackson Street, Suite 1500\u003Cbr>\nChicago, Illinois 60661\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that the FDA investigator was only able to review the conduct of the study by searching through your study director’s email account for the records.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS and Electronic Mail\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nGranger G. C. Hwa, M.D. Ph.D.\n\nRecipient Title\n\nChairman\n\nValley Biosystems\n\n1265 Triangle Court\n\nWest Sacramento, CA 95605\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nCBER-22-002\n\nAugust 3, 2022\n\nDear Dr. Hwa:\n\nThis Warning Letter informs you of objectionable conditions observed during a Food and Drug Administration (FDA) inspection conducted at Valley Biosystems, West Sacramento, California between August 26 and October 8, 2021. FDA investigators met with your staff during the inspection to review your firm’s conduct of the following nonclinical Good Laboratory Practice (GLP) studies:\n\n(b)(4)\n\n(b)(4)\n\nFDA conducted this inspection under the Bioresearch Monitoring Program, which includes inspections designed to review the conduct of research involving investigational products and to help ensure that the data are scientifically valid and accurate, in accordance with Title 21 of the Code of Federal Regulations (CFR), Part 58 – Good Laboratory (GLP) regulations (available at eCFR :: 21 CFR Part 58 -- Good Laboratory Practice for Nonclinical Laboratory Studies), which are requirements promulgated under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262, and section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355, among other provisions. You were not present in person during the inspection but were available via Zoom on September 2, 2021, and October 8, 2021. At the end of the inspection, the FDA investigator presented a Form FDA 483, List of Inspectional Observations (Form FDA 483) and discussed the listed observations with you and your staff.\n\nBased on our review of the Establishment Inspection Report (EIR), the documents submitted with that report, and your firm’s response dated November 1, 2021, to the Form FDA 483 (“Response Letter”), signed by Mr. Cello, we determined that you violated GLP regulations in 21 CFR Part 58. The violations include, but are not limited to the following:\n\n1. Failure to ensure that each individual engaged in the conduct of or responsible for the supervision of a nonclinical laboratory study has education, training, and experience, or a combination thereof, to enable that individual to perform the assigned functions; that each testing facility maintains a current summary of training and experience and job description for each individual engaged in or supervising the conduct of a nonclinical laboratory study; and that for each nonclinical laboratory study, a scientist or other professional of appropriate education, training, and experience, or combination thereof, shall be identified as the study director. [21 CFR §§ 58.29(a), 58.29(b), and 58.33].\n\nYour firm failed to maintain records of trainings that your staff had received to adequately assess their competency and qualifications to perform their assigned tasks for Studies (b)(4). Examples, include, but are not limited to, the following:\n\na. There is no documentation of protocol-specific trainings for the following individuals who participated in these studies:\n\nDr. GGCH, the Chairman of the Board, and Test Facility Management who was involved in editing and reviewing the final reports for Study (b)(4) and Study (b)(4)\n\nThree (3) Veterinarians\n\nGross Pathologist\n\nOperations Manager\n\nDirector of Animal Program & Facilities & Chief Operating Officer\n\nQA Manager\n\nNine (9) Research Technicians\n\nb. Your firm failed to adequately fulfill your regulatory responsibilities by assuring that your study director is qualified and appointed to be the single point of control for Studies (b)(4) and Study (b)(4). Your QA Manager (hereafter referred to as the Quality Assurance Unit (QAU)) stated that your firm’s study director is not a position and is a title on an “as needed” basis.\n\nIn your Response Letter, you expanded your pre-project planning meetings and required Read Only Trainings for all protocols and protocol amendments. We also reviewed your SOP QA25.4, submitted with your Response Letter, and it appears adequate, if properly implemented.\n\nYour firm has also assigned the supplemental GLP training CAPA PA-21-072-01, which was expected to be completed on or before January 31, 2021. We request that you provide all documentation of the GLP training that you have stated to be completed on or before January 31, 2022, including the materials used for the trainings.\n\nIn your Response Letter, you restated your position that the study director is a title at Valley Biosystems, but not a position, and that you therefore do not plan to create a Study Director position description. This approach is not compliant with the applicable requirements. In response to this letter, please review 21 CFR § 58.33, which sets forth the regulatory requirements for the role of the study director, and inform FDA how you intend to comply with this and the other GLP requirements.\n\n2. The study director failed to assure that the protocol, including any change, is approved as provided by 21 CFR § 58.120 and is followed; that all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and that unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and corrective action is taken and documented. Additionally, all data entries shall be dated on the date of entry and signed or initialed by the person entering the data. Any change in entries shall be made so as not to obscure the original entry, shall indicate the reason for such change, and shall be dated and signed or identified at the time of the change. [21 CFR § 58.33 (a)(b)(c) and 21 CFR 58.130(e)]\n\na. The study director failed to assure that the study was conducted according to the protocol and was accurately recorded. Specifically, the section of the study #(b)(4) protocol entitled, “Monitoring of Animal Welfare” required that “signs of animal illness, injury, or pain and distress will be communicated to the Study Director and Sponsor Monitor” and “Recommendations for the treatment of the animals must be approved by the Study Director and Sponsor Monitor.” However, it was not documented that these requirements were met for the following animals:1\n\nAnimal (b)(4) – hemorrhagic diarrhea on 3\u002F2\u002F19 – 3\u002F4\u002F19 and treatment with (b)(4) on 3\u002F2\u002F19.\n\nAnimal (b)(4) –treatment with (b)(4) for trichuris infection on 5\u002F9\u002F19.\n\nAnimal (b)(4) – treatment with (b)(4) for trichuris infection on 1\u002F2\u002F19.\n\nAnimal (b)(4) – treatment with (b)(4) for trichuris infection on 1\u002F2\u002F19.\n\nb. A review of 12 of 12 of the Test Article (TA)\u002FControl Article (CA) Preparation Forms revealed that the name, lot number, and expiration date of reagents and solutions used in preparation of test and control articles were preprinted as opposed to being documented contemporaneously. The documents revealed that the preprinted expiration dates were crossed out and changed, without explanation, by the study director to reflect different expiration dates over a month after the actual date of preparation. This occurred for the following animal source records:\n\nAnimal ID\n\nDate of TA\u002FCA Preparation Completed\n\nDate of change\u002Ffootnote\n\n(b)(4)\n\n9\u002F3\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F5\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F4\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F10\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F6\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F9\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F12\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F16\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F11\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n10\u002F2\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F17\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F18\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F19\u002F19\n\n11\u002F7\u002F19\n\nBecause you failed to ensure that all experimental data were accurately recorded and verified, and that all entries and changes in entries were properly documented, FDA has concerns about the integrity of the data generated from the nonclinical toxicity studies conducted at your testing facility.\n\nIn your Response Letter, you listed SOPs that were revised or are being developed since the inspection, including the revised SOP PA01.7. In your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs not already provided, and documentation of any related trainings.\n\n3. Failure of the QAU to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection. [21 CFR § 58.35(b)(3)].\n\nThe QAU is responsible for monitoring each study to assure management that the facilities, equipment, personnel, methods, practices, records, and controls are in conformance with the GLP regulations. 21 CFR § 58.35(a).\n\na. Your QAU failed to maintain a complete copy of the audit schedule sheet to inspect studies at intervals adequate to assure the integrity of the studies.\n\nb. Your QAU failed to maintain contemporaneously signed and dated documentation or reports of the Critical Phase inspections. Your QAU stated that the Critical Phase inspection results were written directly on the Protocols or on scratch pieces of paper that were thrown away after summarizing the results on the monthly Quality Assurance Status Reports.\n\nYour QAU was not able to provide any source documents of the schedule nor reports for the Critical Phase inspections that were performed for the two GLP studies. We are unable to verify that your QAU audits were adequately conducted according to your SOPs and are in compliance with applicable GLP regulations.\n\nA reliable QAU is integral to the successful completion of any GLP study. Without appropriate QAU oversight, the sponsor and FDA reviewers have no assurance that what is reported in the final study report is accurate. Failure to perform QAU functions calls into question the integrity of both studies.\n\nYour Response Letter explains that you revised SOP QA 10.4 and the accompanying forms; however, you have not developed effective, contemporaneous audit documents that will serve as source documentation of the audits performed by your QAU, for each Critical Phase defined by your SOP. In your response to this letter, please provide audit document templates to accompany your SOP that will serve to demonstrate full compliance with the regulations.\n\n4. Failure to retain all raw data, documentation, protocols, final reports, and specimens (except those specimens obtained from (b)(4) tests and (b)(4)) generated as a result of a nonclinical laboratory study. [ 21 CFR § 58.190(a)].\n\nFor example:\n\na. Twelve (12) of 48 animals surgically treated with the test or control article were missing original source Laboratory Animal Anesthesia Records, which contain details of the surgical procedure for test or control article administration. According to your QAU, the original paper records were discarded once they were scanned and saved electronically.\n\nb. Your firm failed to preserve any source records demonstrating your study director’s adherence to the GLP requirements in regard to his conduct of writing the final reports for Studies (b)(4). Your firm was not able to provide the redline copies of the draft reports, and your QAU stated that the documents had all been deleted.\n\nIn your Response Letter, you stated that your SOPs are being revised following the inspection, but you did not provide supporting documentation of your corrective and preventive actions. Please note that good record keeping and an organized archive that allows for the expedient retrieval of raw data are ways in which your firm can ensure the quality and integrity of the data generated from your GLP nonclinical studies.\n\nIncorrect archiving of study materials affects the integrity and reliability of study data as it prevents accurate retrieval of such data for review, analysis, and verification. Also, failure to have an index prevents data from being readily available, located expeditiously, analyzed, and reconciled when necessary.\n\nIn your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs for archiving source documents, and documentation of any trainings related to this violation.\n\n5. Failure to include in the final report a description of all circumstances that may have affected the quality or integrity of the data for each nonclinical laboratory study. [21 CFR § 58.185(a)(9)].\n\nYou failed to include all data observed for Study (b)(4) in the final Study Report. Data that were not included in the final report include, but are not limited to:\n\nAnimal Number\n\nSource Document\n\nAssessment\u002FComment\n\nAssessment Date\n\n(b)(4)\n\nDaily Clinical Observations\n\nNervous tapping\n\n9\u002F20\u002F19\n\n(b)(4)\n\nFunctional Observation Battery Evaluation\n\nDay 122 post-dose “Out-of Cage” assessment documented abnormal dysmetria, specifically a new comment of “mild crouching of torso when walking tripedally.”\n\n1\u002F16\u002F20\n\n(b)(4)\n\nAnimal Health Record\n\nAcute emesis\n\n02\u002F19\u002F20\n\nWe acknowledge in your Response Letter that you plan to revise SOP QA08.4, Preparation, Review and Approval of Nonclinical Laboratory Study Reports. However, your response cannot be evaluated due to lack of supporting documentation. Please provide a copy of the revised SOP, which you stated will be completed before December 03, 2021, along with documentation of any corrective actions you have implemented thus far.\n\nThe records and final study report of an investigation are crucial to the reconstruction of events leading to the collection and reporting of the data and must reflect the procedure and condition of the study. The information in these essential documents form the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\n\nWe further note during the inspection that the FDA investigators found five (5) reports, “Project Observation Note” (PON), from (b)(4) was the laboratory that you contracted to perform histopathology and immunohistochemical analysis for Study (b)(4). These records revealed numerous comments of poor-quality and insufficient tissue collections received from your firm. Examples of these deviations noted in the PON report from (b)(4), include, but are not limited to, the following:\n\nFor Week-5 Animals, various deficiencies were noted for all spinal cords, all eye tissues, all kidney tissues, all heart tissues, and all larynx tissues.\n\nFor unscheduled death Animal (b)(4), various observations were noted for ureters, salivary gland, adrenal, heart, femur\u002Fsternum bone and marrow, and kidneys.\n\nFor the animals sacrificed at 13 weeks, all brain (b)(4) were received with a (b)(4), except for a few animals. It appears the (b)(4) after processing. In addition, for a certain group of four animals, only one liver was received with a (b)(4) (i.e., (b)(4)).\n\nIn your response to this letter, we request that you provide all documentation and reports, including any corrective action taken that will demonstrate your firm’s investigation and corrective actions taken regarding the numerous tissue sample collection deviations reported to you by (b)(4).\n\nThis letter notifies you of your violations and provides you an opportunity to address the above deficiencies. You should investigate and determine the causes of any violations and take prompt actions to implement corrections to prevent the recurrence of similar violations in current and future studies conducted at your GLP nonclinical laboratory.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your nonclinical studies of investigational new drugs. It is your responsibility to ensure full compliance with the law, including all applicable requirements of the FD&C Act, the PHS Act, and FDA regulations.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter. In your response, please provide written documentation of additional actions you have taken or will take to correct the noted violations and to prevent the recurrence of similar violations in current and future nonclinical laboratory studies.\n\nFailure to adequately address this matter may lead to regulatory action. Failure to respond to this letter and to take appropriate corrective action could result in FDA taking regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to me at the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., WO71-G112, Silver Spring, MD 20993-0002. If you have any questions regarding this letter, please contact the Division of Inspections and Surveillance, CBER at 240-402-8038.\n\nWe also request that you send a copy of your response to the FDA Office listed below.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza, JD\n\nActing Director\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\ncc:\n\nEric Pittman, Director\n\nFDA ORA-BIMO West\n\n550 West Jackson Street, Suite 1500\n\nChicago, Illinois 60661\n\n______________________\n\n1 We note that the FDA investigator was only able to review the conduct of the study by searching through your study director’s email account for the records.","Valley Biosystems","valley-biosystems-632553-08032022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalley-biosystems-632553-08032022","2026-10-26T08:10:19.180269+00:00","Warning Letter","Closed Out","2022-08-09","632553","Biologics","2022-10-18","Granger G. C. Hwa, M.D. Ph.D.","2026-08-20T01:41:07.432+00:00","UPS and Electronic Mail","2022-08-03",{"id":35,"raw":36,"subject":42,"body_html":43,"body_text":44,"firm_name":45,"letter_id":46,"created_at":47,"fei_number":21,"letter_url":48,"updated_at":49,"action_type":24,"case_status":50,"posted_date":51,"marcs_cms_no":52,"product_type":28,"closeout_date":21,"issuing_office":53,"recipient_name":54,"body_fetched_at":55,"delivery_method":56,"recipient_title":21,"reference_number":21,"action_taken_date":57,"medical_device_id":21,"response_letter_date":21},1979,[37,38,39,40,41,13,13,13],"\u003Ctime datetime=\"2023-07-25T13:20:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-05T04:00:00Z\">06\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023\">Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fa>"," Division of Biological Products Operations II","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jon D. Tryggestad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>913 S Main St Ste 215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-7575\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 23-631303\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Lisa Sooter\u003Cbr>\nGeneral Counsel and Co-Owner\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tryggestad and Ms. Sooter:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>Be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of your products manufactured since March 2019, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\u003C\u002Fp>\n\n\u003Cp>c. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\u003C\u002Fp>\n\n\u003Cp>d. You have not established and followed written procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>b. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> only \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong>-forming microorganisms are routinely detected in your environmental samples.\u003C\u002Fp>\n\n\u003Cp>c. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacture of batches nor is there data or rationale for the cleaning agents used.\u003C\u002Fp>\n\n\u003Cp>d. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192].\u003C\u002Fstrong> For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\u003C\u002Fp>\n\n\u003Cp>a. From January 2021 and November 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility failures and \u003Cstrong>(b)(4)\u003C\u002Fstrong> endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include&nbsp;\u003Cem>Cutibacterium acnes, Staphylococcus pasteuri,\u003C\u002Fem> and \u003Cem>Corynebacterium acnes.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>b. From July 2021 and August 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include \u003Cem>Bacillus\u003C\u002Fem> species \u003Cem>non-anthracis, Paenbacillus\u003C\u002Fem> species, and fungi.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assigned a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year expiration date to your products without stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year shelf life and were manufactured under the above-described conditions.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJon D. Tryggestad\n\nRecipient Title\n\nChief Executive Officer and Co-Owner\n\nStratus Biosystems, LLC dba CellGenuity Regenerative Science\n\n913 S Main St Ste 215\n\nGrapevine, TX 76051-7575\n\nUnited States\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWARNING LETTER\n\nJune 5, 2023\n\nWarning Letter #OBPO 23-631303\n\nLisa Sooter\n\nGeneral Counsel and Co-Owner\n\nDear Mr. Tryggestad and Ms. Sooter:\n\nDuring an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).1,2,3 You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.4 Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nBe advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&C Act.\n\nTo lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over (b)(4) vials of your products manufactured since March 2019, include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\n\nb. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\n\nc. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\n\ni. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\n\nii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\n\nd. You have not established and followed written procedures for the (b)(4) sterilization of the (b)(4) filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\n\n2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example:\n\na. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\n\nb. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a (b)(4) only (b)(4). (b)(4)-forming microorganisms are routinely detected in your environmental samples.\n\nc. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning (b)(4) manufacture of batches nor is there data or rationale for the cleaning agents used.\n\nd. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a (b)(4) agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\n\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\n\n4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example:\n\na. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\n\nb. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192]. For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\n\na. From January 2021 and November 2021, your firm has had approximately (b)(4) sterility failures and (b)(4) endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include Cutibacterium acnes, Staphylococcus pasteuri, and Corynebacterium acnes.\n\nb. From July 2021 and August 2021, your firm has had approximately (b)(4) environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include Bacillus species non-anthracis, Paenbacillus species, and fungi.\n\n6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assigned a (b)(4)- to (b)(4)-year expiration date to your products without stability testing.\n\nWe have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a (b)(4)- to (b)(4)-year shelf life and were manufactured under the above-described conditions.\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\n______________________________\n\n1 Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\n\n2 You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\n\n3 Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\n\n4 For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”","Stratus Biosystems, LLC dba CellGenuity Regenerative Science","stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","2026-10-26T08:10:06.541654+00:00","Issued","2023-07-25","631303","Division of Biological Products Operations II","Jon D. Tryggestad","2026-08-20T00:51:52.85+00:00","VIA UNITED PARCEL SERVICE","2023-06-05",{"id":59,"raw":60,"subject":65,"body_html":66,"body_text":67,"firm_name":68,"letter_id":69,"created_at":47,"fei_number":21,"letter_url":70,"updated_at":71,"action_type":24,"case_status":50,"posted_date":72,"marcs_cms_no":73,"product_type":74,"closeout_date":21,"issuing_office":11,"recipient_name":75,"body_fetched_at":76,"delivery_method":77,"recipient_title":21,"reference_number":21,"action_taken_date":78,"medical_device_id":21,"response_letter_date":21},1824,[61,62,63,11,64,13,13,13],"\u003Ctime datetime=\"2023-09-29T19:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-28T04:00:00Z\">09\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finfinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023\">Infinant Health, Inc formerly Evolve Biosystems Inc.\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael D. Johnson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Infinant Health, Inc formerly Evolve Biosystems Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2121 2nd Street, Suite C108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Davis\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95618-6567\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lhannan@infinanthealth.com\"> lhannan@infinanthealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: September 28, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nLisa Hannan, General Counsel, Corporate Secretary, Chief Compliance &amp; Regulatory Officer\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 667715\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Johnson and Ms. Hannan:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s website at www.evivo.com in September 2023 and your marketing materials, including your Evivo with MCT Oil Product Information sheet, which contains directions for purchasing your product, Evivo with MCT Oil (hereinafter, Evivo with MCT Oil or your product). You refer to your product as a probiotic and offer it for sale in the United States. Your product contains \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> EVC001 bacteria, and you market it for use in infants aged 0 to 36 months.\u003C\u002Fp>\n\n\u003Cp>Based on the statements on your website and your Evivo with MCT Oil Product Information sheet, your product is an unapproved new drug and unlicensed biological product, which was introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>Further, your Evivo with MCT Oil product is intended to be added to food for infants, including preterm infants. As described in your Evivo with MCT Oil Product Information sheet, this product is designed specifically for infants in the Neonatal Intensive Care Unit (NICU). Preterm infants are often hospitalized in a NICU. Furthermore, statements on the product page of your website indicate your product is “[e]xclusively for Healthcare Settings” and “made specifically for use in healthcare settings.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\u003C\u002Fp>\n\n\u003Cp>Therefore, in addition to your product being an unapproved new drug and unlicensed biological product, your Evivo with MCT Oil product is an adulterated food under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)], because when intended for consumption by preterm infants, this use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&amp;C Act and the PHS Act. You can find the FD&amp;C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your website at www.evivo.com (last visited on September 28, 2023), through which providers can contact you to purchase your product, includes references to articles that discuss uses for your product in the mitigation, treatment, or prevention of disease, specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants” (article title);\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and\u003C\u002Fli>\n\t\u003Cli>“Probiotics containing B. infantis decrease the risk of necrotizing enterocolitis in premature infants” (from opening summary of article titled, “Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut”).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>As noted above, your website further states that your product is “made specifically for use in healthcare settings,” and your Evivo with MCT Oil Product Information sheet describes the product as “[d]esigned specifically for infants in the NICU[.]”\u003C\u002Fp>\n\n\u003Cp>Because these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Food: Unsafe Food Additive\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition to your product Evivo with MCT Oil being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because under its intended use in food for preterm infants, \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409(a) of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348(a)].\u003C\u002Fp>\n\n\u003Cp>The label of your Evivo with MCT Oil product declares the ingredient “\u003Cem>Bifidobacterium longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> EV C001 (milk, soy)* CFU Count: 8 Billion CFU per 0.5 milliliters.”\u003C\u002Fp>\n\n\u003Cp>Any substance added or intended for addition to food must have premarket approval by FDA for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at Section 201(s)(1)-(6) of the FD&amp;C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under the FD&amp;C Act. There is no food additive regulation that authorizes the use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001.” We are not aware of an applicable exception under section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] for the use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>Infantis\u003C\u002Fem> “EVC001” in conventional foods, including infant formula. We are also not aware of a basis to conclude that any use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>Infantis\u003C\u002Fem> “EVC001” in food for preterm infants, including infant formula, is GRAS.\u003C\u002Fp>\n\n\u003Cp>GRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”) by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (&lt;37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight &lt;1000 grams.” FDA communicated these safety concerns related to use in food for preterm infants during a meeting between the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Additive Safety’s Division of Food Ingredients and Infinant Health on July 7, 2023. In particular, FDA questioned whether the clinical studies Infinant cited in its presentation to FDA were robust enough to support safety, as the studies were short-term, poorly designed, and difficult to interpret without appropriate controls. FDA also noted that short-term clinical studies, in general, are only supportive evidence of safety for the use of living microorganisms and have not served as the primary basis for safety in any GRAS conclusions to date for the use of living microorganisms that have come through the GRAS Notification program.\u003C\u002Fp>\n\n\u003Cp>Therefore, based on our review, FDA has determined that the intended use in food for preterm infants of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> is not GRAS. As such, your EVIVO with MCT oil product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because this use in food for preterm infants of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409 of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>During a meeting with FDA on September 21, 2023, your firm emphasized to Agency representatives the benefits of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> in Evivo with MCT Oil for preterm infants in neonatal intensive care units, including by reducing the incidence of necrotizing enterocolitis. These statements suggest that similar claims may exist in other labeling or promotional materials that may be inaccessible to FDA.\u003C\u002Fp>\n\n\u003Cp>We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&amp;C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector, Office of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FTobias-OHSU-NEC-Publication.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FUnderwood_2015_pr2014156.pdf.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nBiologics\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMichael D. Johnson\n\nRecipient Title\n\nCEO\n\nInfinant Health, Inc formerly Evolve Biosystems Inc.\n\n2121 2nd Street, Suite C108\n\nDavis, CA 95618-6567\n\nUnited States\n\nlhannan@infinanthealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nDate: September 28, 2023\n\nLisa Hannan, General Counsel, Corporate Secretary, Chief Compliance & Regulatory Officer\n\nRE: 667715\n\nDear Mr. Johnson and Ms. Hannan:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s website at www.evivo.com in September 2023 and your marketing materials, including your Evivo with MCT Oil Product Information sheet, which contains directions for purchasing your product, Evivo with MCT Oil (hereinafter, Evivo with MCT Oil or your product). You refer to your product as a probiotic and offer it for sale in the United States. Your product contains B. longum subsp. infantis EVC001 bacteria, and you market it for use in infants aged 0 to 36 months.\n\nBased on the statements on your website and your Evivo with MCT Oil Product Information sheet, your product is an unapproved new drug and unlicensed biological product, which was introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. These violations are described in more detail below.\n\nFurther, your Evivo with MCT Oil product is intended to be added to food for infants, including preterm infants. As described in your Evivo with MCT Oil Product Information sheet, this product is designed specifically for infants in the Neonatal Intensive Care Unit (NICU). Preterm infants are often hospitalized in a NICU. Furthermore, statements on the product page of your website indicate your product is “[e]xclusively for Healthcare Settings” and “made specifically for use in healthcare settings.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\n\nTherefore, in addition to your product being an unapproved new drug and unlicensed biological product, your Evivo with MCT Oil product is an adulterated food under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)], because when intended for consumption by preterm infants, this use of B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&C Act.\n\nAs explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&C Act and the PHS Act. You can find the FD&C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drug and Unlicensed Biological Product\n\nYour website at www.evivo.com (last visited on September 28, 2023), through which providers can contact you to purchase your product, includes references to articles that discuss uses for your product in the mitigation, treatment, or prevention of disease, specifically:\n\n“Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants” (article title);1 and\n\n“Probiotics containing B. infantis decrease the risk of necrotizing enterocolitis in premature infants” (from opening summary of article titled, “Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut”).2\n\nAs noted above, your website further states that your product is “made specifically for use in healthcare settings,” and your Evivo with MCT Oil Product Information sheet describes the product as “[d]esigned specifically for infants in the NICU[.]”\n\nBecause these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nPlease be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdulterated Food: Unsafe Food Additive\n\nIn addition to your product Evivo with MCT Oil being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because under its intended use in food for preterm infants, B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409(a) of the FD&C Act [21 U.S.C. §§ 321(s) and 348(a)].\n\nThe label of your Evivo with MCT Oil product declares the ingredient “Bifidobacterium longum subsp. infantis EV C001 (milk, soy)* CFU Count: 8 Billion CFU per 0.5 milliliters.”\n\nAny substance added or intended for addition to food must have premarket approval by FDA for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at Section 201(s)(1)-(6) of the FD&C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under the FD&C Act. There is no food additive regulation that authorizes the use of B. longum subsp. infantis “EVC001.” We are not aware of an applicable exception under section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] for the use of B. longum subsp. Infantis “EVC001” in conventional foods, including infant formula. We are also not aware of a basis to conclude that any use of B. longum subsp. Infantis “EVC001” in food for preterm infants, including infant formula, is GRAS.\n\nGRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”) by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (\u003C37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight \u003C1000 grams.” FDA communicated these safety concerns related to use in food for preterm infants during a meeting between the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Additive Safety’s Division of Food Ingredients and Infinant Health on July 7, 2023. In particular, FDA questioned whether the clinical studies Infinant cited in its presentation to FDA were robust enough to support safety, as the studies were short-term, poorly designed, and difficult to interpret without appropriate controls. FDA also noted that short-term clinical studies, in general, are only supportive evidence of safety for the use of living microorganisms and have not served as the primary basis for safety in any GRAS conclusions to date for the use of living microorganisms that have come through the GRAS Notification program.\n\nTherefore, based on our review, FDA has determined that the intended use in food for preterm infants of B. longum subsp. infantis is not GRAS. As such, your EVIVO with MCT oil product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because this use in food for preterm infants of B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409 of the FD&C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\n\nDuring a meeting with FDA on September 21, 2023, your firm emphasized to Agency representatives the benefits of B. longum subsp. infantis in Evivo with MCT Oil for preterm infants in neonatal intensive care units, including by reducing the incidence of necrotizing enterocolitis. These statements suggest that similar claims may exist in other labeling or promotional materials that may be inaccessible to FDA.\n\nWe advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector, Office of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nCc: (b)(4)\n\n____________________\n\n1 https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FTobias-OHSU-NEC-Publication.pdf.\n\n2 https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FUnderwood_2015_pr2014156.pdf.","Infinant Health, Inc formerly Evolve Biosystems Inc.","infinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finfinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023","2026-10-26T08:08:58.729306+00:00","2023-09-29","667715","BiologicsFood & Beverages","Michael D. Johnson","2026-08-20T00:37:59.96+00:00","VIA UPS and Electronic Mail","2023-09-28",3,{"510k":81,"classification":82,"enforcement":83,"event":84,"event_backfill":85,"pma":86,"warning_letter":87},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]